Italia markets open in 1 hour 15 minutes
Dow Jones
38.589,16 -57,94 (-0,15%) Nasdaq
17.688,88 +21,28 (+0,12%) Nikkei 225
38.077,18 -737,38 (-1,90%) EUR/USD
1,0707 -0,0002 (-0,02%) Bitcoin EUR
62.083,28 +262,50 (+0,42%) CMC Crypto 200
1.409,12 -8,75 (-0,62%)
CSL Ltd (CSJ.DU)
Dusseldorf - Dusseldorf Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
Alla chiusura: 07:30PM CEST
| Chiusura precedente | 177,26 |
| Aperto | 176,86 |
| Denaro | 0,00 x 0 |
| Domanda | 0,00 x 0 |
| Min-Max giorno | 176,84 - 178,46 |
| Intervallo di 52 settimane | 135,10 - 183,80 |
| Volume | |
| Media Volume | 0 |
| Capitalizzazione | N/D |
| Beta (mensile su 5 anni) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | 13 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireuniQure announces achievement of $100 million milestone related to hemophilia B gene therapy
Milestone payment triggered by first commercial sale of HEMGENIX® in U.S. by CSL BehringLEXINGTON, Mass. and AMSTERDAM, June 20, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced the achievement of a $100 million milestone associated with the first commercial sale of HEMGENIX® in the United States by its partner, global biotechnology leader CSL (ASX: CSL). HEMGENIX® (etranacoge
© 2024 Yahoo. Tutti i diritti riservati.